This trial is studying the recommended dosage of a combination of imetelstat and ruxolitinib to treat myelofibrosis, as well as the safety and effectiveness of this dosage.
3 Primary · 13 Secondary · Reporting Duration: From first dose of imetelstat treatment up to approximately 5 years
41 Total Participants · 1 Treatment Group
Primary Treatment: Imetelstat · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: